Genmab Rises After FDA Grants Breakthrough Therapy Status
This article is for subscribers only.
Genmab A/S rose the most in almost two months after U.S. regulators granted “breakthrough therapy” designation to an experimental cancer drug the Danish company is developing with Johnson & Johnson.
Genmab surged 8.7 percent, the most since March 8, to close at 157 kroner in Copenhagen. That’s the highest price since August 2009.